drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
CD20-targeted monoclonal antibody (375 mg/m2 ×2) that depletes CD20+ B cells via ADCC, CDC, and apoptosis to limit new donor-specific anti-HLA antibody production.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Rituximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Rituximab is a CD20-targeted monoclonal IgG1 that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis, thereby reducing formation of donor-specific anti-HLA antibodies.
drug_name
Anti-CD20 monoclonal antibody
nct_id_drug_ref
NCT06177561